Background: Nusinersen is approved for the treatment of 5q spinal muscular atrophy of all types and stages in patients of all ages. Although clinical trials have shown improvements in motor function in infants and children treated with the drug, data for adults are scarce. We aimed to assess the safety and efficacy of nusinersen in adults with 5q spinal muscular atrophy.
Methods: We did an observational cohort study at ten academic clinical sites in Germany. Patients with genetically confirmed 5q spinal muscular atrophy (age 16-65 years) with a homozygous deletion of exons 7, 8, or both, or with compound heterozygous mutations were eligible for inclusion and received nusinersen treatment in accordance with the label for a minimum treatment time of 6 months to a follow-up of up to 14 months. The primary outcome was the change in the total Hammersmith Functional Motor Scale Expanded (HFMSE) score, assessed at months 6, 10, and 14, and based on pre-post comparisons. This study is registered with the German Clinical Trials Register (number DRKS00015702).
Findings: Between July 13, 2017, and May 1, 2019, 173 patients were screened, of whom 139 (80%) were eligible for data analysis. Of these, 124 (89%) were included in the 6-month analysis, 92 (66%) in the 10-month analysis, and 57 (41%) in the 14-month analysis; patients with missing baseline HFMSE scores were excluded from these analyses. Mean HFMSE scores were significantly increased compared with baseline at 6 months (mean difference 1·73 [95% CI 1·05-2·41], p<0·0001), 10 months (2·58 [1·76-3·39], p<0·0001), and 14 months (3·12 [2·06-4·19], p<0·0001). Clinically meaningful improvements (≥3 points increase) in HFMSE scores were seen in 35 (28%) of 124 patients at 6 months, 33 (35%) of 92 at 10 months, and 23 (40%) of 57 at 14 months. To 14-month follow-up, the most frequent adverse effects among 173 patients were headache (61 [35%] patients), back pain (38 [22%]), and nausea (19 [11%]). No serious adverse events were reported.
Interpretation: Despite the limitations of the observational study design and a slow functional decline throughout the natural disease course, our data provide evidence for the safety and efficacy of nusinersen in the treatment of adults with 5q spinal muscular atrophy, with clinically meaningful improvements in motor function in a real-world cohort.
Copyright © 2020 Elsevier Ltd. All rights reserved.
Safety and Treatment Effects of Nusinersen in Longstanding Adult 5q-SMA Type 3 - A Prospective Observational Study.J Neuromuscul Dis. 2019;6(4):453-465. doi: 10.3233/JND-190416. J Neuromuscul Dis. 2019. PMID: 31594243 Free PMC article. Clinical Trial.
Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study.Lancet. 2016 Dec 17;388(10063):3017-3026. doi: 10.1016/S0140-6736(16)31408-8. Epub 2016 Dec 7. Lancet. 2016. PMID: 27939059 Clinical Trial.
Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy.N Engl J Med. 2018 Feb 15;378(7):625-635. doi: 10.1056/NEJMoa1710504. N Engl J Med. 2018. PMID: 29443664 Clinical Trial.
Nusinersen: A Treatment for Spinal Muscular Atrophy.Ann Pharmacother. 2019 Jan;53(1):61-69. doi: 10.1177/1060028018789956. Epub 2018 Jul 16. Ann Pharmacother. 2019. PMID: 30008228 Review.
Physical exercise training for type 3 spinal muscular atrophy.Cochrane Database Syst Rev. 2019 Mar 1;3(3):CD012120. doi: 10.1002/14651858.CD012120.pub2. Cochrane Database Syst Rev. 2019. PMID: 30821348 Free PMC article. Review.
Cited by 2 articles
Histone Deacetylases Inhibitors in Neurodegenerative Diseases, Neuroprotection and Neuronal Differentiation.Front Pharmacol. 2020 Apr 24;11:537. doi: 10.3389/fphar.2020.00537. eCollection 2020. Front Pharmacol. 2020. PMID: 32390854 Free PMC article. Review.
[New treatments for spinal muscular atrophy].Nervenarzt. 2020 Apr;91(4):294-302. doi: 10.1007/s00115-020-00871-7. Nervenarzt. 2020. PMID: 32076758 Review. German.